Home > Resources > Whitepapers > Enabling Genomics-Guided Precision Medicine

Enabling Genomics-Guided Precision Medicine

September 18, 2018

The era of precision medicine has arrived, and with it, a tidal wave of data from disparate sources, including electronic health records (EHRs), lab systems, pathology, and genomics. By integrating data from all available sources and analyzing it in smart ways, clinicians can finally get a complete picture of an individual’s medical profile and define a truly personalized approach to care.

Spotlight

DDD Group Limited

DDD Limited comprises a group of companies which between them offer a complete service to take a health and beauty product from idea to a consumer’s shopping basket. At DDD, we have been making and selling health and beauty products for almost 100 years, and all the skills we have gained in that time are available to you. Our operating companies are run as separate business units, but can all work together to deliver a range of services to our partners. All of our businesses operate with our core purpose at the forefront of how we work: Helping people be at their best in a way we can be proud of.

OTHER WHITEPAPERS

The Use of Real-World Data for Personalized Medicine

whitePaper | June 5, 2022

Although our growing scientific understanding and improvements made in medical technology lead to significant advances in human health and wellbeing, many therapy strategies remain insufficient,

Patients Diagnosed with Post-COVID Conditions

whitePaper | May 18, 2022

Post-COVID conditions, also known by such terms as long COVID and post-acute sequelae of COVID-19, have become an issue of growing national concern.

Pharma R And D Review

whitePaper | February 11, 2021

Welcome to Pharmaprojects’ 2021 review of trends in pharmaceutical R&D. For almost 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article I’ll examine the state of play at the start of 2021.

Adapting to Pharma’s Next Normal

whitePaper | October 4, 2022

Let’s just say what we’re all thinking: 2020 was rough. It threw every element of our lives into disarray. We suddenly had to become experts at navigating a new way of working, schooling and socialising. It was disruptive and it was challenging, but it was also transformative

Simcyp™ PBPK for Drug-Drug Interactions (DDI)

whitePaper | July 4, 2023

The past two decades have witnessed transformative changes in our approach to using modeling & simulation to assess and manage DDIs. Multidisciplinary innovations in mechanistic assessment of absorption, distribution, metabolism, and excretion (ADME), population pharmacology and pharmacogenetics.

More Whitepapers

Enabling Genomics-Guided Precision Medicine